m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01286)
Name
NSC-95397
Synonyms
NSC 95397; 93718-83-3; 2,3-Bis(2-hydroxyethylthio)-1,4-naphthalenedione; NSC95397; NSC-95397; 2,3-bis(2-hydroxyethylsulfanyl)naphthalene-1,4-dione; MLS002153403; CHEMBL429095; SMR001230781; SR-01000075930; 1,4-Naphthalenedione, 2,3-bis[(2-hydroxyethyl)thio]-; Tocris-1547; AC1Q6JAF; Lopac-N-1786; Lopac0_000629; KBioGR_000495; BSPBio_001155; KBioSS_000495; SCHEMBL2530685; AC1L66Q4; cid_262093; KBio3_000910; KBio2_005631; KBio2_003063; CHEBI:93193; KBio3_000909; KBio2_000495; CTK3I8111; DTXSID10294236; MolPort-003-958-936; HMS3268C19
    Click to Show/Hide
Status
Investigative
Structure
Formula
C14H14O4S2
InChI
1S/C14H14O4S2/c15-5-7-19-13-11(17)9-3-1-2-4-10(9)12(18)14(13)20-8-6-16/h1-4,15-16H,5-8H2
InChIKey
MAASHDQFQDDECQ-UHFFFAOYSA-N
PubChem CID
262093
TTD Drug ID
D0J1KH
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
M-phase inducer phosphatase 2 (MPIP2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for NSC-95397. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NSC-95397 through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). [1], [2]
References
Ref 1 METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression. Exp Hematol Oncol. 2022 Mar 14;11(1):14. doi: 10.1186/s40164-022-00256-3.
Ref 2 Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. doi: 10.1016/j.bmcl.2005.12.080. Epub 2006 Jan 24.